

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Riomet (metformin oral solution) Riomet ER (metformin extended-release oral suspension)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Riomet (metformin oral solution) 500 mg/5mL Riomet ER (metformin extended-release oral suspension) 500 mg/5mL	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Riomet (metformin oral solution) may be approved if the following criteria are met:

- I. Individual is unable to swallow the oral tablet dose form due to a clinical condition such as but not limited to the following:
 - A. Dysphagia; **OR**
 - B. Individual's age.

Requests for Riomet ER (metformin extended-release oral suspension) may be approved if the following criterion is met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to Riomet (metformin oral solution); **AND**
- II. Individual is unable to swallow the oral tablet dose form due to a clinical condition such as but not limited to the following:
 - A. Dysphagia;
 - OR**
 - B. Individual's age.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Note:

Metformin agents have a black box warning for lactic acidosis. Post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias. Risk factors include renal impairment, concomitant use of certain agents, age > 65 years, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake and hepatic impairment. If lactic acidosis is suspected, discontinue the metformin agent and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: January 2, 2020.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et. al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. *Endocrine Practice*. 2019;25:69-100.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2020; Updated periodically.
5. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Last updated: November 14, 2017. Available at <https://www.fda.gov/Drugs/DrugSafety/ucm493244.htm>. Accessed: January 2, 2020.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.